Clinical trials such as the MD Anderson Cancer Centre's BATTLE phase II study, which randomizes patients to second line treatment based on 11 biomarkers including EGFR, KRAS, BRAF, Cyclin D1, VEGF, VEGFR-2, and RXR will no doubt explore the feasibility of the “personalized medicine” approach to the management of NSCLC [81,82]. The gene discussed is VEGFA; the disease is non-small cell lung carcinoma.